Expertise in
13
conditions

Dr. Erlene K. Seymour

Hematology
Office
4201 Saint Antoine St Ste 7B, 
Detroit, MI 
Expertise in
13
conditions
Office
4201 Saint Antoine St Ste 7B, 
Detroit, MI 

Overview

Erlene Seymour is a Hematologist practicing medicine in Detroit, Michigan.

Dr. Seymour is highly rated in 13 conditions, according to our data. Her clinical expertise encompasses Chronic B-Cell Leukemia (CBCL), Chronic Lymphocytic Leukemia (CLL), Diffuse Large B-Cell Lymphoma (DLBCL), and Sickle Cell Disease.

She is actively involved in clinical research, co-authoring 23 peer reviewed articles and participating in 18 clinical trials.

Specialties

Hematology

Licenses

Internal Medicine in MI

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

McLaren Health
  • HMO

Locations

Office
4201 Saint Antoine St Ste 7B, Detroit, MI 48201

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

18 Clinical Trials

A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Ibrutinib, Obinutuzumab, Venetoclax
Study Phase: Phase 3
A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)
A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Drug, Biological, Other
Study Drugs: Ibrutinib, Obinutuzumab, Venetoclax
Study Phase: Phase 3
A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: August 04, 2026
Intervention Type: Drug, Biological, Procedure, Other, Radiation
Study Drugs: Brentuximab, Dacarbazine, Doxorubicin, Filgrastim, Nivolumab, Pegfilgrastim, Vinblastine
Study Phase: Phase 3
A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Enrollment Status: Active_not_recruiting
Publish Date: July 22, 2026
Intervention Type: Drug, Other
Study Drugs: Brentuximab vedotin, Rituximab, Lenalidomide
Study Phase: Phase 3
A Phase II Pilot Study of Metformin Therapy in Patients With Relapsed Chronic Lymphocytic Leukemia and Untreated CLL Patients With Genomic Deletion 11q
A Phase II Pilot Study of Metformin Therapy in Patients With Relapsed Chronic Lymphocytic Leukemia and Untreated CLL Patients With Genomic Deletion 11q
Enrollment Status: Completed
Publish Date: July 20, 2026
Intervention Type: Drug
Study Drug: Metformin
Study Phase: Phase 2
A Randomized 3-Arm Phase II Study Comparing 1.) Bendamustine, Rituximab and High Dose Cytarabine (BR/CR) 2.) Bendamustine, Rituximab, High Dose Cytarabine and Acalabrutinib (BR/CR-A), and 3.) Bendamustine, Rituximab and Acalabrutinib (BR-A) in Patients </= 70 Years Old With Untreated Mantle Cell Lymphoma
A Randomized 3-Arm Phase II Study Comparing 1.) Bendamustine, Rituximab and High Dose Cytarabine (BR/CR) 2.) Bendamustine, Rituximab, High Dose Cytarabine and Acalabrutinib (BR/CR-A), and 3.) Bendamustine, Rituximab and Acalabrutinib (BR-A) in Patients </= 70 Years Old With Untreated Mantle Cell Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: July 17, 2026
Intervention Type: Biological, Drug
Study Drugs: Acalabrutinib, Bendamustine, Bendamustine Hydrochloride, Cytarabine, Rituximab
Study Phase: Phase 2
Phase I/II Study of Ixazomib and Romidepsin in Relapsed/ Refractory Peripheral T-cell Lymphoma (PTCL)
Phase I/II Study of Ixazomib and Romidepsin in Relapsed/ Refractory Peripheral T-cell Lymphoma (PTCL)
Enrollment Status: Terminated
Publish Date: May 06, 2026
Intervention Type: Drug
Study Drugs: Romidepsin, Ixazomib
Study Phase: Phase 1/Phase 2
A Phase I Trial of the Combination of Lenalidomide and Blinatumomab in Patients With Relapsed or Refractory Non-Hodgkins Lymphoma (NHL)
A Phase I Trial of the Combination of Lenalidomide and Blinatumomab in Patients With Relapsed or Refractory Non-Hodgkins Lymphoma (NHL)
Enrollment Status: Completed
Publish Date: November 26, 2025
Intervention Type: Biological, Drug
Study Drugs: Blinatumomab, Lenalidomide
Study Phase: Phase 1
A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL)
A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL)
Enrollment Status: Completed
Publish Date: November 21, 2025
Intervention Type: Drug
Study Drug: Brentuximab
Study Phase: Phase 2
A Multicenter, Phase 1/2 Study of Selinexor in Combination With Backbone Treatments or Novel Therapies in Patients With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)
A Multicenter, Phase 1/2 Study of Selinexor in Combination With Backbone Treatments or Novel Therapies in Patients With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)
Enrollment Status: Withdrawn
Publish Date: October 03, 2025
Intervention Type: Drug
Study Drugs: Selinexor, Rituximab, Bendamustine, Polatuzumab Vedotin, Ibrutinib, Lenalidomide, Tafasitamab, Venetoclax, Gemcitabine, Oxaliplatin
Study Phase: Phase 1/Phase 2
View 9 Less Clinical Trials

23 Total Publications

Real-World Outcomes Among Medicare Beneficiaries Treated with Bruton Tyrosine Kinase Inhibitors for Treatment-Naïve CLL.
Real-World Outcomes Among Medicare Beneficiaries Treated with Bruton Tyrosine Kinase Inhibitors for Treatment-Naïve CLL.
Journal: Oncology and therapy
Published: April 21, 2026
Similar Doctors
Expertise in
24
conditions
Expertise in
24
conditions
Referral may be required

Karmanos Cancer Center

4100 John R St, 
Detroit, MI 
 (0.4 miles away)
313-576-8730
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Jeffrey Zonder is a Hematologist practicing medicine in Detroit, Michigan. Dr. Zonder is highly rated in 24 conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Primary Amyloidosis, Relapsed Refractory Multiple Myeloma (RRMM), Bone Marrow Transplant, and Vertebroplasty. Dr. Zonder is currently accepting new patients.

Expertise in
20
conditions
Expertise in
20
conditions
Referral may be required

Karmanos Cancer Center

4100 John R St, 
Detroit, MI 
 (0.4 miles away)
800-527-6266
Languages Spoken:
English, Mandarin, Thai
See accepted insurances
Accepting New Patients

Voravit Ratanatharathorn is a Hematologist practicing medicine in Detroit, Michigan. Dr. Ratanatharathorn is highly rated in 20 conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML), Graft Versus Host Disease (GvHD), and Bone Marrow Transplant. Dr. Ratanatharathorn is currently accepting new patients.

Expertise in
32
conditions
Dr. Jay Yang
Hematology
Expertise in
32
conditions
Dr. Jay Yang
Hematology
Referral may be required

Office

4100 John R St, 
Detroit, MI 
 (0.4 miles away)
800-527-6266
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Jay Yang is a Hematologist practicing medicine in Detroit, Michigan. Dr. Yang is highly rated in 32 conditions, according to our data. His clinical expertise encompasses Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Leukemia, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Yang is currently accepting new patients.

Frequently Asked Questions about Dr. Erlene K. Seymour

How do I make an appointment with Dr. Erlene K. Seymour?

You can book an appointment with Dr. Erlene K. Seymour by calling their office at 313-745-2554. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Erlene K. Seymour a top-rated expert for Chronic B-Cell Leukemia (CBCL)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Erlene K. Seymour is classified as an Distinguished expert for Chronic B-Cell Leukemia (CBCL), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Erlene K. Seymour specialize in?

While Dr. Erlene K. Seymour is a Hematology, they have specific expertise in Chronic B-Cell Leukemia (CBCL), Chronic Lymphocytic Leukemia (CLL), and Diffuse Large B-Cell Lymphoma (DLBCL). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Erlene K. Seymour participate in research or clinical trials?

Yes. Dr. Erlene K. Seymour has published 23 articles and abstracts on conditions like Chronic B-Cell Leukemia (CBCL). You can view a list of Dr. Erlene K. Seymour's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Erlene K. Seymour accept my insurance?

Dr. Erlene K. Seymour accepts most major insurance plans, including McLaren Health. We recommend calling the office directly at 313-745-2554 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Seymour's expertise for a condition
ConditionClose
    View All 12 Advanced Conditions
    View All 11 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile